Text Correction
The authors would like to add the following clarification regarding the clinical trials evaluating the probiotic product VSL#3 cited in the published paper []. A correction has been made to Paragraph 1 in Section 3.2. Effectiveness of Conventional Probiotics in Clinical Trials. “All studies cited in this paper assessed a probiotic formulation previously known as VSL#3. The formulation of the probiotic product VSL#3, which is currently marketed under this brand name, is not identical to the original product, which since 2016 has been known under the generic name ‘De Simone Formulation’ and is available on the market under the brand names Visbiome (USA) and Vivomixx (Europe).”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Štofilová, J.; Kvaková, M.; Kamlárová, A.; Hijová, E.; Bertková, I.; Gul’ašová, Z. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. Biomedicines 2022, 10, 2236. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).